The
#AIEye Episode 343: Intel (NasdaqGS: $INTC) Acquires MaaS Firm Moovit and IBM
(NYSE: $IBM) Unveils Watson AIOps
Global
#AI in Drug Discovery Market to Reach $1.434 Billion by 2024
Point Roberts WA, Vancouver BC – May 5, 2020 – Investorideas.com (www.investorideas.com), a global investor news source covering
Artificial Intelligence (AI) brings you today’s edition of The
AI Eye- watching stock news, deal tracker and advancements in
artificial intelligence.
Listen
to today’s podcast:
Read
this in full at https://www.investorideas.com/news/2020/artificial-intelligence/05051AIEye-INTC-IBM.asp
Today’s
Column- The
AI Eye- Watching stock news, deal tracker and advancements
in artificial intelligence
Stocks
discussed: (NasdaqGS:INTC) (NYSE:IBM)
Intel Corporation (NasdaqGS:INTC) has acquired mobility-as-a-service (MaaS)
solutions company Moovit for approximately $900 million. Moovit provides
AI-powered mobility solutions, the addition of which “brings Intel’s Mobileye
closer to achieving its plan to become a complete mobility provider,” according
to the press release. Intel CEO Bob Swan said:
"Intel’s
purpose is to create world-changing technology that enriches the lives of every
person on Earth, and our Mobileye team delivers on that purpose every day.
Mobileye’s ADAS [advanced driver-assistance systems] technology is already
improving the safety of millions of cars on the road, and Moovit accelerates
their ability to truly revolutionize transportation – reducing congestion and
saving lives – as a full-stack mobility provider."
IBM (NYSE:IBM) has announced the unveiling of IBM Watson AIOps,
described as “a new offering that uses AI to automate how enterprises
self-detect, diagnose and respond to IT anomalies in real time.” In tandem, IBM
is releasing the Accelerator for Application Modernization with AI, which
“leverages continuous learning and interpretable AI models to adapt to the client's
preferred software engineering practices and stays up-to-date with the
evolution of technology and platforms.” Rob Thomas, Senior Vice President,
Cloud and Data Platform, IBM, explained:
"What
we've learned from companies all over the world is that there are three major
factors that will determine the success of AI in business – language,
automation and trust. The COVID-19 crisis and increased demand for remote work
capabilities are driving the need for AI automation at an unprecedented rate
and pace. With automation, we are empowering next generation CIOs and their
teams to prioritize the crucial work of today's digital enterprises—managing
and mining data to apply predictive insights that help lead to more impactful
business results and lower cost."
Global
AI in Drug Discovery Market to Reach $1.434 Billion by 2024
A report from Markets and Markets finds that the global AI
in Drug Discovery market will grow from $259 million in 2019 to $1.434 billion
by 2024 with a compound annual growth rate (CAGR) of 40.8 percent in the
forecast period. An excerpt from the report description reads:
The
growth of the artificial intelligence in drug discovery market is primarily
driven by factors such as the growing number of cross-industry collaborations
and partnerships, the increasing need to control drug discovery &
development costs and reduce the overall time taken in this process, the rising
adoption of cloud-based applications & services, and the impending patent
expiry of blockbuster drugs.
On
the other hand, a lack of data sets in the field of drug discovery and the
inadequate availability of skilled labor are some of the factors challenging
the growth of the market.
Sam Mowers, Investorideas.com
For
a list of artificial intelligence stocks on Investorideas.com visit
here
or become an Investor Ideas member
About Investorideas.com - News that
Inspires Big Investing Ideas Investorideas.com is a
recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move
podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
The
Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com,
iHeartRadio and Google Play Music.
Visit
the Podcast page at Investorideas.com:
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure is posted for each compensated news release, content published
/created if required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions. More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
The AI Eye- Watching stock
news, deal tracker and advancements in artificial intelligence is an
original content brand of Investorideas.com
Contact
Investorideas.com
800
665 0411
No comments:
Post a Comment